VMS and Menopause: KNDy Neurons, NK Receptors, and Practical Insights - Episode 7
Malignancy Risks of Neurokinin Receptor Antagonists
Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.
What does data from the clinical trials suggest about the incidence of neoplasms with fezolinetant and elinzanetant?
Notes:Across 3 clinical trials, fezolinetant is associated with a small, but higher incidence of endometrial hyperplasia or endometrial malignancy.
There were no cases of endometrial hyperplasia or endometrial malignancy observed with elinzanetant in a long-term safety study.
